Targeted radiation therapy for treating acute myeloid leukemia
Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia
This study is testing new types of radiation treatments for people with relapsed or hard-to-treat acute myeloid leukemia (AML) to make them safer and more effective, especially for older patients or those with other health problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11132214 on NIH RePORTER |
What this research studies
This research focuses on developing innovative radiation therapies to treat patients with relapsed and refractory acute myeloid leukemia (AML). It aims to improve treatment outcomes by using targeted radioimmunotherapy and total marrow irradiation, which specifically targets cancerous cells while minimizing damage to healthy tissues. The approach is designed to be safer and more effective, particularly for older patients or those with other health issues who may not tolerate traditional treatments well. By enhancing the precision of radiation delivery, the study seeks to reduce relapse rates and improve overall survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed or refractory acute myeloid leukemia, particularly older adults or those with comorbidities.
Not a fit: Patients with early-stage acute myeloid leukemia or those who do not have relapsed or refractory disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with acute myeloid leukemia, potentially leading to better survival rates.
How similar studies have performed: Previous studies have shown promising results with similar targeted radiation therapies, indicating potential for success in this novel approach.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Wong, Jeffrey Y — Beckman Research Institute/city of Hope
- Study coordinator: Wong, Jeffrey Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.